Takeda announced 634 layoffs in 2026, affecting 1% of its 49,000-person workforce. The company cited $1.3b restructuring. 634 us jobs via warn notice. vyvanse patent loss cratered revenue. cutting to fund new drug launches. new ceo julie kim takes over june. The cuts are part of a broader pattern of workforce reductions across the Pharma sector in 2026, where companies are restructuring operations in response to changing market conditions, AI adoption, and margin pressure.